Selvita SA

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: PLSLVCR00029
PLN
32.10
-0.1 (-0.31%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Poor Management Efficiency with a low ROCE of 5.35%

  • The company has been able to generate a Return on Capital Employed (avg) of 5.35% signifying low profitability per unit of total capital (equity and debt)
2

The company is Net-Debt Free

3

High Debt company with Weak Long Term Fundamental Strength

 
4

The company has declared Negative results for the last 4 consecutive quarters

5

With ROE of -0.92%, it has a risky valuation with a 2.51 Price to Book Value

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

PLN 642 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.32

stock-summary
Return on Equity

0.25%

stock-summary
Price to Book

2.00

Revenue and Profits:
Net Sales:
93 Million
(Quarterly Results - Dec 2025)
Net Profit:
7 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-25.87%
0%
-25.87%
6 Months
-22.28%
0%
-22.28%
1 Year
-18.11%
0%
-18.11%
2 Years
-54.4%
0%
-54.4%
3 Years
-57.82%
0%
-57.82%
4 Years
-58.37%
0%
-58.37%
5 Years
-54.14%
0%
-54.14%

Selvita SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
9.61%
EBIT Growth (5y)
-21.24%
EBIT to Interest (avg)
4.94
Debt to EBITDA (avg)
1.60
Net Debt to Equity (avg)
0.40
Sales to Capital Employed (avg)
0.75
Tax Ratio
49.04%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.35%
ROE (avg)
10.42%

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.51
EV to EBIT
124.60
EV to EBITDA
14.77
EV to Capital Employed
2.09
EV to Sales
2.49
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
1.68%
ROE (Latest)
-0.92%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 5.11% vs -5.78% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 911.11% vs 80.43% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "92.60",
          "val2": "88.10",
          "chgp": "5.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "19.10",
          "val2": "15.80",
          "chgp": "20.89%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.60",
          "val2": "2.40",
          "chgp": "50.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "7.30",
          "val2": "-0.90",
          "chgp": "911.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "61.40%",
          "val2": "28.00%",
          "chgp": "3.34%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 6.58% vs -1.44% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 113.11% vs -108.73% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "364.50",
          "val2": "342.00",
          "chgp": "6.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "61.80",
          "val2": "48.90",
          "chgp": "26.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "11.00",
          "val2": "12.40",
          "chgp": "-11.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.80",
          "val2": "-6.10",
          "chgp": "113.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "19.90%",
          "val2": "-12.40%",
          "chgp": "3.23%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQstock-summary

Dec'25
Sep'25
Change(%)
Net Sales
92.60
88.10
5.11%
Operating Profit (PBDIT) excl Other Income
19.10
15.80
20.89%
Interest
3.60
2.40
50.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
7.30
-0.90
911.11%
Operating Profit Margin (Excl OI)
61.40%
28.00%
3.34%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is 5.11% vs -5.78% in Sep 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 911.11% vs 80.43% in Sep 2025

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
364.50
342.00
6.58%
Operating Profit (PBDIT) excl Other Income
61.80
48.90
26.38%
Interest
11.00
12.40
-11.29%
Exceptional Items
0.00
0.00
Consolidate Net Profit
0.80
-6.10
113.11%
Operating Profit Margin (Excl OI)
19.90%
-12.40%
3.23%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 6.58% vs -1.44% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 113.11% vs -108.73% in Dec 2024

stock-summaryCompany CV
About Selvita SA stock-summary
stock-summary
Selvita SA
Pharmaceuticals & Biotechnology
Selvita SA, formerly Selvita Cro SA, is a Poland-based integrated service company active in the pharmaceutical and biotechnology industries. The Company is engaged in providing multidisciplinary solutions supporting customers and projects within area of drug discovery, regulatory studies, as well as research and development. It offers its clients drug discovery support at every stage of the early discovery phase up to preclinical research, from target validation up to the selection of a clinical candidate. Also, it offers services at every stage of the drug discovery process in the field of drug testing and bioanalytical analyses, from development and validation of methods, stability studies, to routine quality control testing. The Company cooperates with numerous research institutes and universities from Europe and the United States.
Company Coordinates stock-summary
Company Details
Park Life Science, ul. Bobrzynskiego 14 , KRAKOW None : 30-348
stock-summary
Tel: 48 12 2974700
stock-summary
Registrar Details